Abbey farma and Daiichi Snakyo España sign an agreement for the promotion of Trosid in Spain. Abbey will be responsible for the presentation of product to physicians. Trosid, a tioconazole based product, is indicated in the treatment of onycomicosis (fungal infections in the nails) caused by dermatophytes and sensible yeasts. Daiichi Sankyo received contractual rights for the commercialization of Trosid in Spain granted by Pfizer España, the research company owner of tiaconazole and marketing holder of Trosid in Spain.
Comments are closed.